Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial

What Was Tested

Researchers studied Insulin Glargine and Insulin Lispro in this randomized controlled trial publication.

The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes (T2D) achieve glycaemic targets.

Primary objective compared the HbA1c change from baseline.

Who Took Part

The abstract describes 471 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Nothing was hidden in this open-label Insulin Glargine study: the patients and staff both knew the treatment.

More than one site took part, so the patients came from several places.

ILPS was injected once or twice daily vs. glargine injected once daily plus prestudy OAMs.

What Was Measured

The subject headings attached to it are Body Mass Index, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Insulin Glargine, Insulin Lispro and Insulin, Long-Acting.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Glargine and Insulin Lispro in 471 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Glargine compound page and the Insulin Lispro compound page.